🇺🇸 GLOFITAMAB in United States

1,619 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Cytokine Release Syndrome — 466 reports (28.78%)
  2. Disease Progression — 254 reports (15.69%)
  3. Death — 169 reports (10.44%)
  4. Off Label Use — 160 reports (9.88%)
  5. Neutropenia — 154 reports (9.51%)
  6. Pyrexia — 113 reports (6.98%)
  7. Febrile Neutropenia — 88 reports (5.44%)
  8. Covid-19 — 82 reports (5.06%)
  9. Anaemia — 68 reports (4.2%)
  10. Drug Ineffective — 65 reports (4.01%)

Source database →

GLOFITAMAB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is GLOFITAMAB approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for GLOFITAMAB in United States?

Marketing authorisation holder not available in our data.